Medivation's Board of Directors Unanimously Rejects Sanofi's Unsolicited Proposal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Medivation's Board of Directors Unanimously Rejects Sanofi's Unsolicited Proposal

Medivation (MDVN) PT Raised to $63 at Credit Suisse on M&A Valuation

May 3, 2016 7:27 AM EDT

Credit Suisse analyst Kenneth MacKay raised his price target on Medivation (NASDAQ: MDVN) to $63.00 (from $49.00) as he moves to a M&A valuation. The firm maintained an Outperform rating.

MacKay continues to see Sanofi's $52.50/share offer as significantly undervaluing the pipeline and continue to... More

Stifel Raises Medivation Inc (MDVN) PT to $66 with Company In Play

May 2, 2016 7:19 AM EDT

Stifel analyst, Thomas Shrader, tries to sort through the buyout hype surrounding Medivation (NASDAQ: MDVN) in a note this morning. Recent news reports make it pretty clear Medivation is in play but like many biotechnology stories the value of the company is based on many assumptions. His takeaway is that a fair price would be $66 and possibly as high as $85... More

Sanofi (SNY) Issues Commentary on Medivation's (MDVN) Rejection of Takeover Proposal; Remains Committed to Combination

April 29, 2016 9:06 AM EDT

Sanofi (NYSE: SNY) commented on Medivation, Inc.'s (Nasdaq: MDVN) rejection of Sanofi's non-binding all-cash proposal to acquire Medivation for $52.50 per share:

Combining Sanofi and... More